908 Devices (MASS) to Release Quarterly Earnings on Monday

908 Devices (NASDAQ:MASS) will likely be releasing its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect 908 Devices to post earnings of ($0.12) per share and revenue of $13.5780 million for the quarter. 908 Devices has set its FY 2025 guidance at EPS.Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 8:30 AM ET.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.02). 908 Devices had a negative net margin of 30.54% and a negative return on equity of 24.30%. The business had revenue of $4.70 million during the quarter, compared to analysts’ expectations of $12.17 million. On average, analysts expect 908 Devices to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

908 Devices Stock Performance

NASDAQ:MASS opened at $7.98 on Monday. 908 Devices has a one year low of $1.81 and a one year high of $9.34. The firm has a market cap of $286.16 million, a price-to-earnings ratio of -14.78 and a beta of 0.45. The firm’s fifty day moving average is $7.44 and its two-hundred day moving average is $6.67.

Insider Buying and Selling at 908 Devices

In related news, CFO Joseph H. Iv Griffith sold 5,000 shares of the company’s stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $7.07, for a total transaction of $35,350.00. Following the completion of the transaction, the chief financial officer owned 97,930 shares in the company, valued at $692,365.10. This represents a 4.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 10,000 shares of company stock worth $80,593. 23.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in shares of 908 Devices during the 2nd quarter worth about $48,000. Daiwa Securities Group Inc. acquired a new position in shares of 908 Devices during the 2nd quarter worth about $61,000. The Manufacturers Life Insurance Company acquired a new position in shares of 908 Devices during the 2nd quarter worth about $77,000. Walleye Capital LLC acquired a new position in shares of 908 Devices during the 2nd quarter worth about $82,000. Finally, Rhumbline Advisers raised its position in shares of 908 Devices by 5.5% during the 2nd quarter. Rhumbline Advisers now owns 36,416 shares of the company’s stock worth $260,000 after purchasing an additional 1,894 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Analyst Ratings Changes

MASS has been the subject of a number of analyst reports. Leerink Partners upgraded shares of 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research report on Tuesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, October 8th. Leerink Partnrs upgraded shares of 908 Devices from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen upgraded shares of 908 Devices from a “sell” rating to a “hold” rating in a research report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, 908 Devices currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.